Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of multi-peptide vaccination and PSMAxCD3 bispecific antibody in biochemical relapse of prostate cancer
2025-522144-41-00Phase 2Authorised
- Sponsor
- University Hospital Tübingen
- Start
- Jul 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of CC-1 in prostate cancer (PCa) (3 arms), sponsored by University Hospital Tübingen. Planned start Jul 2026; status: authorised.
02
Drugs
CC-1
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2025-522144-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522144-41-00.